As part of its ‘Explore’ programme, Elbow Beach Capital has invested in biomaterial innovators, Zentraxa.
Biomaterials can fundamentally alter the performance of everyday products. The difficulty is finding methods that allow you to make these biomaterials at sufficient scale. Zentraxa is solving this problem using its proprietary Zentide platform which can produce novel peptides with unique properties.
Founded in 2017 as a spin-out from the University of Bristol, Zentraxa specialises in the design, production & testing of biomaterials for medical and industrial purposes. The company aims to become one of the front-runners in developing novel biomaterials leveraging its unique process and sustainable, bespoke solutions.
Elbow Beach Capital were immediately impressed with Zentraxa and its team. Jonathan Wogel leads a capable and committed group with a valuable purpose at the centre of their culture. We believe that Zentraxa’s work has the potential to transform the biomaterials industry.
Jonathan Wogel, Executive Chair & Director of Zentraxa:
“Following investment from Elbow Beach Capital, Zentraxa is excited to further develop our unique platform technology and to design new, innovative biomaterial solutions with our commercial partners. This funding from Elbow Beach Capital and our other investors will allow us to achieve significant R&D and commercial milestones in the coming months. I look forward to working closely with JP and the Elbow Beach team as we work towards achieving these milestones.”
In line with our ambition to create value and impact by backing innovative founders, our ‘Explore’ investment vertical widens our reach beyond our ‘Core’ investments. Typically, companies receiving ‘Explore’ investment are pre-seed and not yet ready to go to market. Our ‘Explore’ tickets allow us to support and build relationships with emerging businesses with the potential of future larger investments.